This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (28)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Donald J. D'Amico, MD; Paul R. Skolnik, MD; Barry R. Kosloff; Paula Pinkston, MD; Martin S. Hirsch, MD; Robert T. Schooley, MD
Boston

Arch Ophthalmol. 1988;106(9):1168-1169.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Cytomegalovirus (CMV) retinitis is a substantial cause of morbidity in patients with acquired immunodeficiency syndrome (AIDS). Recently, a beneficial effect of treatment with ganciclovir, an acyclovir derivative with activity against CMV in vitro, has been reported.¹

Zidovudine (formerly known as azidothymidine [AZT]) is a dideoxythymidine compound with antiviral activity against human immunodeficiency virus (HIV). This study documents regression of CMV retinitis in a patient with AIDS who elected to receive zidovudine therapy without ganciclovir treatment.

Report of a Case.

—A 26-year-old homosexual man was diagnosed as having AIDS in July 1986, when he developed Pneumocystis carinii pneumonia. In addition, CMV and Mycobacterium avium intracellulare were recovered from a bronchoalveolar lavage specimen at this time. He recovered after three weeks of trimethoprim and sulfamethoxazole therapy. On Sept 23, 1986, he was examined for a complaint of blurred vision in his left eye. Visual acuity was 20/20 . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?